Abstract
Abstract
Background
Higher income population tend to prefer brand-name to generic drugs, which may cause disparity in access to brand-name drugs among income groups. A potential policy that can resolve such disparity is imposing a greater co-payment rate on high-income enrollees. However, the effects of such policy are unknown. We examined how patients’ choice between brand-name and generic drugs are affected by the unique income-based co-payment rates in Japan; 10% for general enrollees and 30% for those with high income among the elderly aged 75 and over.
Methods
We drew on cross-sectional price variation among commonly prescribed 311 drugs using health insurance claims data from a large prefecture in Japan between October 2013 and September 2014 to identify between-income-group differences in responses to differentiated payments.
Results
Running 311 multivariate logistic regression models controlling individual demographics, the median estimate indicated that high-income group was 3% (odds ratio = 0.97) less likely to choose a generic drug than the general-income group and the interquartile estimates ranged 0.92–1.02. The multivariate feasible generalized least squares model indicated high-income group’s higher likelihood to choose brand-name drugs than the general-income group without co-payment rate differentiation (p < 0.001). Such gap in the likelihood was attenuated by 0.4% (p = 0.027) with an US$1 increase in the difference in additional payment/month for brand-name drugs between income groups — no gap with US$10 additional payment/month. This attenuation was observed in drugs for chronic diseases only, not for acute diseases.
Conclusions
Income-based co-payment rates appeared to reduce disparity in access to brand-name drugs across income groups, in addition to reducing total medical expenditure among high-income group who shifted from brand-name drugs to generic ones due to larger drug price differences.
Funder
JSPS KAKENHI
Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Organisation for Economic Cooperation and Development. Health at a Glance 2017. OECD; 2017.
2. van Doorslaer E, Wagstaff A, Rutten F, editors. Equity in the Finance and Delivery of Health Care: An International Perspective. Oxford: Oxford University Press; 1992.
3. Van Doorslaer E, Masseria C, Koolman X. Inequalities in access to medical care by income in developed countries. C Can Med Assoc J. 2006;174:177–83.
4. Becker GS. Health as human capital: synthesis and extensions. Oxf Econ Pap. 2007;59:379–410.
5. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart AM, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease. JAMA. 2008;300:2514–26.
https://doi.org/10.1001/jama.2008.758
.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献